Pevion gains $30.2M in first round

Germany's Pevion Biotech has landed a $30.2 million Series A private financing round. The round was led by the new investor BZ Bank Aktiengesellschaft. BB Biotech Ventures II, CC Private Equity Partners and Bachem Holding also participated. Pevion has three of its vaccines in clinical testing. The company said it will use the funds to push a hepatitis C and breast cancer vaccines into Phase II. It will also fund preclinical vaccine candidates against RSV and Candida infections into clinical development.

- see the release

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.